Blackstone Group is betting on your family tree.

The alternative asset manager is set to buy about 75% of, the business known for family history research and DNA testing, in a deal valued at $4.7 billion including debt, according to people familiar with the transaction. Singaporean sovereign-wealth fund GIC, which took a stake in 2016, will hold about 25%, said the people, who asked not to be identified because the information is private. It will be the first acquisition by Blackstone’s largest ever private equity fund.

Representatives for Blackstone and declined to comment.

New York-based Blackstone is flush with cash as investors continue to bet big on the firm amid the uncertainty caused by the Covid-19 pandemic. Executives have in recent months touted success in navigating the 2008 financial crisis to show that the business, which has $156 billion in dry powder, will be well positioned to benefit from the current upheavals.

Based in Lehi, Utah, has more than 3 million paying subscribers and more than 18 million people in its DNA network. It sells at-home DNA testing kits to customers, competing with 23andMe. first went public in 2009, raising $100 million. It was taken private in 2012 in a $1.6 billion buyout led by private equity firm Permira, and on at least two occasions since has considered going public again, though it never got the valuation it was seeking.

Many of Blackstone’s recent investments have been in growth companies and businesses likely to benefit from shifts in consumer behavior. Last month, the group announced it was investing in Oatly — a plant-based drink that’s been rapidly growing in popularity — with partners including Oprah Winfrey. Blackstone also owns a majority stake in MagicLab, the owner of dating app Bumble.


Deal talks regarding started a few months ago, when much of the world was still at home and looking for things to do, said the people with knowledge of discussions. The deal could be announced as early as Wednesday, they said.

Silver Lake and GIC acquired a majority stake four years ago in a deal that valued the company at $2.6 billion. Prior owners, including management, Permira and Spectrum Equity, currently have a minority interest in the business.

Blackstone, the world’s largest alternative asset manager with $564 billion in assets, is also focused on growing its life sciences group. It has spent more than $1 billion this year investing in drugs that target high cholesterol, kidney disease in children and devices for diabetes patients.

Early in 2020, the firm bought $11 billion of public equities and liquid debt as values sank and markets became more volatile. It also took stakes in companies including 21Vianet, a Chinese data center business, and a portfolio of Hollywood film studios.